Mirviss Jeffrey B.'s Form 4 filing
Boston Scientific Corp (BSX) · filed Feb 21, 2023
- Accession no.
- 0001225208-23-002378
- Filed
- Feb 21, 2023
- Trade date
- Feb 16-18, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 8 non-derivative transactions and 3 derivative transactions. Open-market sales total $161.5K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mirviss Jeffrey B.CIK 0001566094 | Officer (EVP&Pres, Periph Intervent) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 16, 2023 | Common Stock | MOption exerciseAcquired | +2,970 | $0.00F1 | $0 | 92,858 | Direct | |
| Feb 16, 2023 | Common Stock | FTax withholdingDisposed | −909 | $46.48 | −$42,250.32 | 91,949 | Direct | |
| Feb 16, 2023 | Common Stock | SSaleDisposed | −1,409 | $46.79 | −$65,927.11 | 90,540 | Direct | |
| Feb 17, 2023 | Common Stock | MOption exerciseAcquired | +3,333 | $0.00F1 | $0 | 93,873 | Direct | |
| Feb 17, 2023 | Common Stock | FTax withholdingDisposed | −1,020 | $46.54 | −$47,470.8 | 92,853 | Direct | |
| Feb 17, 2023 | Common Stock | SSaleDisposed | −2,061 | $46.35 | −$95,527.35 | 90,792 | Direct | |
| Feb 18, 2023 | Common Stock | MOption exerciseAcquired | +2,817 | $0.00F3 | $0 | 93,609 | Direct | |
| Feb 18, 2023 | Common Stock | FTax withholdingDisposed | −1,002 | $46.54 | −$46,633.08 | 92,607 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 16, 2023 | Common Stock | MOption exerciseDisposed | −2,970 | $0.00 | $0 | 8,910 | Direct | |
| Feb 17, 2023 | Common Stock | MOption exerciseDisposed | −3,333 | $0.00 | $0 | 6,667 | Direct | |
| Feb 18, 2023 | Common Stock | MOption exerciseDisposed | −2,817 | $0.00 | $0 | 2,817 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
Referenced by the price of 2 transactions in Table I.
- F3
Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock.
Referenced by the price of 1 transaction in Table I.